耳鼻咽喉科臨床
Online ISSN : 1884-4545
Print ISSN : 0032-6313
ISSN-L : 0032-6313
薬物
成人急性中耳炎および急性鼻副鼻腔炎に対するLevofloxacin 500 mg 1日1回投与の有用性に関する検討
山中 昇杉田 麟也鈴木 賢二横山 道明林 泰弘眞田 文明藤原 久郎渡邊 敬田渕 富三
著者情報
ジャーナル 認証あり

2011 年 104 巻 8 号 p. 591-605

詳細
抄録

In pharmacokinetic and clinical studies of once daily 500 mg levofloxacin (LVFX) in adults with acute otitis media or acute rhinosinusitis, we assessed disease severity and LVFX efficacy using scoring based on local findings and clinical symptoms.
The LVFX tissue concentration of 2.25 to 5.83 hours after single 500 mg administration was 6.010±2.477 μg/g (mean±SD) in the maxillary sinus mucosa, with a tissue/plasma concentration ratio of 1.51±0.43. The clinical efficacy (test of cure) was 100% (13/13) in acute otitis media and acutely exacerbated chronic otitis media, 85.1% (63/74) in acute rhinosinusitis, and 90.9% (10/11) in acutely exacerbated chronic rhinosinusitis. Bacteriological eradication was 94.9% (37/39) in acute rhinosinusitis and 100% in acute otitis media (4/4) and acutely exacerbated chronic rhinosinusitis (3/3). Adverse reactions, all mild to moderate, occurred in 33.6% (38/113). Side effects, but no serious or clinically significant event, occurred in 22.1% (25/113).
In conclusion, LVFX once daily 500 mg p.o. entered well into maxillary sinus tissue and appears useful in treating otitis media and rhinosinusitis. Data confirmed that scoring was very useful in deciding appropriate otitis media and rhinosinusitis treatment.

著者関連情報
© 2011 耳鼻咽喉科臨床学会
前の記事 次の記事
feedback
Top